newsfilter
← Earnings
Earnings Releases·

Corvus Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Cash and marketable securities increased to $202.9 million as of September 30, 2026, from $56.8 million at year-end 2025, driven by $189.4 million in net financing proceeds, extending the cash runway into the second quarter of 2028.
  • Operating expenses and net losses rose significantly for the three and nine months ended September 30, 2026, with total operating expenses reaching $21.4 million (vs. $10.6 million) and net loss widening to $52.0 million for the nine-month period (vs. $3.0 million).
  • The company is advancing its soquelitinib pipeline with the SIERRA1 Phase 2 atopic dermatitis trial enrolling, a Phase 1b hidradenitis suppurativa trial active, and a Phase 2 asthma trial planned for Q1 2027, alongside the ongoing registrational Phase 3 PTCL trial.
  • Key data milestones are anticipated in 2027, including top-line results from the Angel Pharmaceuticals atopic dermatitis cohort in March 2027 and initial hidradenitis suppurativa data in the first half of the year.
Company
CORVUS PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology